Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells

  • Authors:
    • Chong-Zhi Wang
    • Jing-Tian Xie
    • Bin Zhang
    • Ming Ni
    • Anna Fishbein
    • Han H. Aung
    • Sangeeta R. Mehendale
    • Wei Du
    • Tong-Chuan He
    • Chun-Su Yuan
  • View Affiliations

  • Published online on: November 1, 2007     https://doi.org/10.3892/ijo.31.5.1149
  • Pages: 1149-1156
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In this study, we evaluated the effects of Panax notoginseng root extract (NGRE) and its major constituents on SW480 human colorectal cancer cells. We used high performance liquid chromatography to determine the contents of major saponins in NGRE. The anti-proliferative effects were evaluated by the cell counting method, and concentration-related anti-proliferative effects were observed. At 1.0 mg/ml, NGRE inhibited cell growth by 85.8% (P<0.01), probably linked to the higher concentration of ginsenosides Rb1 and Rg1. The pharmacologic activities of notoginsenoside R1 and ginsenosides Rg1 and Rb1 on the cells were antiproliferative. We tested the effects of NGRE on DNA synthesis by measuring [3H]-thymidine incorporation. NGRE induced cell apoptosis at 0.5 and 1 mg/ml. Two-day treatment with 300 µM of notoginsenoside R1, ginsenosides Rg1 and Rb1 increased cell apoptosis significantly. Cell cycle and cyclin A assay showed that NGRE arrested cells in the synthesis phase and increased the expression of cyclin A remarkably. NGRE also enhanced the actions of two chemotherapeutic agents, 5-fluorouracil and irinotecan. Cell growth decreased more with the combined treatment of NGRE and 5-fluorouracil (or irinotecan) than with the chemotherapy agent applied alone, suggesting that notoginseng can reduce the dose of 5-fluorouracil (or irinotecan) needed to achieve desired effects. Further in vivo and human trials are warranted to test whether notoginseng is a valuable chemo-adjuvant with clinical validity.

Related Articles

Journal Cover

November 2007
Volume 31 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang C, Xie J, Zhang B, Ni M, Fishbein A, Aung HH, Mehendale SR, Du W, He T, Yuan C, Yuan C, et al: Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. Int J Oncol 31: 1149-1156, 2007
APA
Wang, C., Xie, J., Zhang, B., Ni, M., Fishbein, A., Aung, H.H. ... Yuan, C. (2007). Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells. International Journal of Oncology, 31, 1149-1156. https://doi.org/10.3892/ijo.31.5.1149
MLA
Wang, C., Xie, J., Zhang, B., Ni, M., Fishbein, A., Aung, H. H., Mehendale, S. R., Du, W., He, T., Yuan, C."Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells". International Journal of Oncology 31.5 (2007): 1149-1156.
Chicago
Wang, C., Xie, J., Zhang, B., Ni, M., Fishbein, A., Aung, H. H., Mehendale, S. R., Du, W., He, T., Yuan, C."Chemopreventive effects of Panax notoginseng and its major constituents on SW480 human colorectal cancer cells". International Journal of Oncology 31, no. 5 (2007): 1149-1156. https://doi.org/10.3892/ijo.31.5.1149